CURRICULUM VITAE

EDUCATION AND TRAININGEDUCATION:

1971 Stanford University, B.A.1976 Harvard University, M.D.

POST GRADUATE TRAINING:

Internship: 1976-1977 Pediatrics, Children’s Hospital Boston, Boston, MassachusettsResidency: 1977-1978 Pediatrics, Children’s Hospital Boston, Boston, Massachusetts

1978-1979 Pediatrics, Children’s Hospital and Regional Medical Center, Seattle, Washington

Fellowship: 1979-1981 Ambulatory Pediatrics and Community Medicine, Children’s Hospital and Regional Medical Center, Seattle, Washington

APPOINTMENTS AND POSITIONS

FACULTY:

1998- Vice Chair for Research, Department of Pediatrics, University of Washington School of Medicine

1997- Professor, Department of Pediatrics, University of Washington School of Medicine1996- Associate Program Director, University of Washington General Clinical Research Center1994-2006 Associate Program Director, Core Center for Gene Therapy1992-1997 Associate Professor, Pediatrics, University of Washington School of Medicine1986-1992 Assistant Professor, Pediatrics, University of Washington School of Medicine1983-1986 Lecturer, Pediatrics, University of Washington School of Medicine1980-1983 Acting Instructor, Pediatrics, University of Washington School of Medicine1979-1980 Acting Instructor/Senior Fellow, Pediatrics/Ambulatory Pediatrics and Community

Medicine, University of Washington1978-1979 Senior Resident, Pediatrics, Children's Orthopedic Hospital and Medical Center,

University of Washington School of Medicine1976-1978 Clinical Instructor, Pediatrics, Boston Children's Hospital and Medical Center, Harvard

Medical School

HOSPITAL:

2007- Center Director, Clinical and Translational Research, Seattle Children's1998- Director, CF Therapeutics Development Network Coordinating Center, Seattle Children’s1996-2007 Co-Director, General Clinical Research Center Pediatric Satellite, Children’s Hospital

and Regional Medical Center1980-1998 Director, Cystic Fibrosis, Children’s Hospital and Regional Medical Center

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 1 -

1980-1990 Director, Ambulatory Care Clinic and Cystic Fibrosis Center, Children’s Hospital and Regional Medical Center

BOARD CERTIFICATION AND LICENSURE

Organization Year

American Board of Pediatrics, Subspecialty Pulmonology 1992- American Board of Pediatrics 1981Washington State 1978-National Board of Medical Examiners 1977

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

Organization Year

Association of American Physicians 2006-American Pediatric Society 2000-American Thoracic Society 1992-American Academy of Pediatrics 1981-Member, Washington State Medical Society 1980-Member, King County Medical Society 1980-

HONORS

Title of Award Year

Leader for the Follow a Leader contest sponsored by Macy’s, King 5 TV and The Seattle Times 2008UW GCRC Lifetime Achievement Award 20072007 Dr. Alvin J. Thompson Award 2007Helen S. Jackson Woman of Valor Award (Presented by Senators Maria 2006Cantwell and Hilary Clinton)National Library of Medicine Women of Distinction (McDermott nominated) 2005Bonnie W. Ramsey, M.D. Endowed Chair in Cystic Fibrosis 2005Bonnie Ramsey Endowed Professorship 2003Cystic Fibrosis Foundation Paul di’Sant Agnese Award 1998Doris F. Tulcin Cystic Fibrosis Research Award 1997Marion Fay Award for Outstanding Women Physician Scientist Nominee 1993-1996"Best Doctors in America" Acknowledgement 1993-1996Medical Achievement Recognition Award, Cystic Fibrosis Foundation 1990Resident Teaching Award 1988Medical Achievement Recognition Award, Cystic Fibrosis Foundation 1986Honors in the field of Hematology - Harvard Medical School 1976

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 2 -

Phi Beta Kappa - Stanford University 1972

EDITORIAL AND ADVISORY BOARDS

2009- International Scientific Advisory Board (ISAB)2006- Associate Editor, Journal of Cystic Fibrosis2000- Editorial Board, American Journal of Critical Care Medicine1997-2003 Chair, Medical Advisory Council, National Cystic Fibrosis Foundation, Bethesda,

Maryland2000 Member, Advisory Group on Pharmaceutical Sponsored Research in GCRCs to the

Director of NCRR1996-1999 Member, Medical Advisory Board, Tyloxaxol Corp.1996-1998 Member, Pulmonary Advisory Board, Food and Drug Administration, Rockville,

Maryland1994-1997 Vice Chair, Medical Advisory Council, National Cystic Fibrosis Foundation, Bethesda,

Maryland1994-1997 Co-Editor, Insights in Cystic Fibrosis. CME course accredited by UW School of

Medicine1995-1996 Ad Hoc Reviewer, New England Journal of Medicine, Journal of Pediatrics, Human

Gene Therapy, Pediatric Pulmonology, American Journal of Respiratory and Critical Care Medicine

1995 Member, Advisory Review Group, NHLBI, National Institutes of Health, Bethesda, Maryland

1992-1993 Member, Medical Advisory Board, Genentech, Inc., South San Francisco, California1990-1993 Member, Medical Advisory Council, National Cystic Fibrosis Foundation, Bethesda,

Maryland

SPECIAL RESPONSIBILITIES

NATIONAL:

2009- Reviewer, National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Special Emphasis Panel

2008- Chair-Elect, CTSA Consortium Child Health Oversight Committee (CC-CHOC)2006- Member, National Heart, Lung and Blood Institute (NHLBI) Data Safety Monitoring Board for

pulmonary clinical trials2003-2004 Member, National Academy of Sciences Institute of Medicine, Committee on Clinical Research

Involving Children2001-2003 Member, National Academy of Sciences Institute of Medicine, Committee on Assessing the

System for Protecting Human Research Subjects2000-2002 Member, Executive Committee, GCRC Program Directors Association2000 Member, Cystic Fibrosis Foundation Therapeutics, Inc. Board of Trustees1998- Chair, CF Therapeutics Development Network Steering Committee1996 Member, Special Review Group, NIDDK, National Institutes of Health, Bethesda, Maryland

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 3 -

1994-1998 Chair, Clinical Research Committee, Cystic Fibrosis Foundation1994-2003 Member, Board of Trustees, Cystic Fibrosis Foundation, Bethesda, Maryland1994 Member, Special Review Group, National Institutes of Health, Bethesda, Maryland1993 Member, Special Review Group for Gene Therapy Center, NHLBI, NIH, Bethesda, Maryland1993-1995 Ad Hoc Reviewer, Medical Research Council of Canada1993 Ad Hoc Reviewer, Medical Research Council, Great Britain1990-1993 Chair, Center Committee, National Cystic Fibrosis Foundation, Bethesda, Maryland1989-1990 Vice Chair, Center Committee, National Cystic Fibrosis Foundation, Bethesda, Maryland1983-1993 Member, Center Committee, National Cystic Fibrosis Foundation, Rockville, Maryland

LOCAL:

A. University of Washington:

2006- Member, Awards and Prizes Committee2000-2004 Chair, RR Wing Space Committee2000-2004 Member, Appointments and Promotions Council1994-1996 Chair, Scientific Advisory Committee, GCRC1995-1996 Member, Faculty Senate Special Committee on Faculty Women1994-1996 Member, Council for Scientific Affairs1984-1986 Member, Medical Student Thesis1981-1984 Member, Medical Student Education

B. Children's Hospital and Medical Center:

2005-2006 Chair, Bioethics Search Committee2003-2006 Chair, Clinical Research Steering Committee2002-2006 Member, Research Oversight Committee2000- Ad Hoc Member, Pediatric Scientific Advisory Committee for GCRC1994-1995 Member, Department of Medicine Quality Improvement/Peer Review Committee1984-1986 Member-at-Large, Medical Executive Committee1982-1994 Member, Institutional Review Board1980-1986 Member, Pharmacy and Therapeutics

PUBLICATIONSRefereed articles

1. Levy J, Smith AL, Kenny MA, Ramsey BW, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983;148(6):1069-76.

2. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105(1):117-24.

3. Muller-Soyano A, Ramsey BW, Glader BE. Comparative monovalent cation transport in neonatal and adult red blood cells. Pediatr Res 1984;18(8):778-80.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 4 -

4. Izutsu K, Johnson D, Schubert M, Wang E, Ramsey B, Tamarin A, Truelove E, Ensign W, Young M. Electron microprobe analysis of human labial gland secretory granules in cystic fibrosis. J Clin Invest 1985;75(6):1951-6.

5. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis R. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis. Am Rev Respir Dis 1985;132(4):761-5.

6. Ramsey BW, Marcuse EK, Foy HM, Cooney MK, Allan I, Brewer D, Smith AL. Use of bacterial antigen detection in the diagnosis of pediatric lower respiratory tract infections. Pediatrics 1986;78(1):1-9.

7. Izutsu K, Ensign W, Ramsey B, Schubert M, Allan B, Truelove E. Autonomic regulation of potassium release from human labial salivary glands in vitro. Arch Oral Biol 1988;33(7):519-23.

8. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, Schwartz R, Thomassen M, Williams-Warren J, Weber A, Wilmott R, Wilson H, Yogev R. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112(4):547-54.

9. Izutsu K, Ensign WY, Ramsey BW, Schubert MM, Allan BJ, Truelove EL. Potassium release in labial glands from controls and patients with cystic fibrosis. Lab Invest 1989;60(1):158-60.

10. Ramsey BW, Gore EJ, Smith AL, Cooney MK, Redding GJ, Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 1989;143(6):662-8.

11. Davis RL, Mendelman P, Ramsey B, Smith AL. Tobramycin dosage recommendation in patients with cystic fibrosis. Infection 1989;17(1):41.

12. Smith AL, Ramsey B, Redding G, Haas J. Endobronchial infection in cystic fibrosis. Acta Paediatr Scand (Suppl) 1989;363:31-6.

13. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7(4):265-71.

14. Allan BJ, Izutsu KT, Ramsey BW, Schubert MM, Ensign WY, Truelove EL. Cyclic nucleotide responses in control and cystic fibrosis labial glands. Am J Physiol 1990;258(6 Pt 2):R1320-6.

15. de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990;47(1):73-8.

16. Schidlow DV, Ramsey BW, Chesrown S, et al. Cystic Fibrosis Foundation: Guidelines for patient services, evaluation and monitoring in cystic fibrosis centers. Am J Dis Child 1990;144:1311-12.

17. Hutabarat R M, Unadkat JD, Sahajwalla C, McNamara S, Ramsey B, Smith AL. Disposition of drugs in cystic fibrosis I: Sulfamethoxazole and trimethoprim. Clin Pharmacol Ther 1991;49(4):402-9.

18. Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, Hedges DL, Gibson R, Redding

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 5 -

GJ, Lent K, Harris K. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144(2):331-7.

19. Weber A, de Groot R, Ramsey B, Williams-Warren J, Smith A. Probenecid pharmacokinetics in cystic fibrosis. Dev Pharmacol Ther 1991;16(1):7-12.

20. Waller DG, Fleming JS, Ramsey B, Gray J. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate. Postgrad Med J 1991;67(783):42-6.

21. Ramsey BW, Farrell PM, Pencharz P, Consensus Committee. Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr 1992;55(1):108-16.

22. Ramsey B, Richardson M. Impact of sinusitis in cystic fibrosis. J Allergy Clin Immunol 1992:90(3 Pt 2):547-52.

23. Rosenfeld M, Ramsey BW. Evolution of airway microbiology in the infant with cystic fibrosis: role of non-pseudomonal and pseudomonal pathogens. Semin Respir Infect1992;7(3):158-67.

24. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA. Efficacy of aerosol administration of tobramycin in patients with cystic fibrosis. New Eng J Med 1993;328(24):1740-6.

25. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, Wilmott RW, Wohl ME, Meyerson LJ, Shak S, Fuchs H, Smith AL. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148(1):145-51.

26. Wang JP, Unadkat JD, al-Habet SMH, O'Sullivan TA, Williams-Warren J, Smith AL, Ramsey B. Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clin Pharmacol Ther 1993;54(3):293-302.

27. Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993;103(4):1096-9.

28. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993;8:53-66. Review.

29. Marshall SG, Ramsey BW. Aerosol therapy in CF, DNase, tobramycin. Sem Respir Ther 1993;15:434-8.

30. Marshall SG, Ramsey BW. Sinus disease in the patient with cystic fibrosis. Immunol Clin N Am 1993;14;185-91.

31. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis: Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;124(2):177-92. Review.

32. Weber A, Smith A, Williams-Warren J, Ramsey B, Covert DS. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994;17(5):331-9.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 6 -

33. Wang JP, Unadkat JD, McNamara S, O'Sullivan TA, Smith AL, Trager WF, Ramsey B. Disposition of drugs in cystic fibrosis: VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1994;55(5):528-34.

34. Henderson WR, Astley SJ, McCready MM, Kushmerick P, Casey S, Becker JW, Ramsey BW. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994;124(3):400-8.

35. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME, Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331(10):637-42.

36. Ramsey BW, Dorkin HL. Consensus Conference: Practical applications of pulmozyme. Pediatr Pulmonol 1994;17(6):404-8.

37. Henderson WR Jr, Astley SJ, Ramsey BW. Liver function in patients with cystic fibrosis ingesting fish oil. J Pediatr 1994;125(3):504-5.

38. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 1995;62(Suppl 1):19-24.

39. Smith AL, Ramsey BW. Aerosol administration of antibiotics. Pediatr Pulmonol Suppl 1995;11:68-9.

40. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995;39(1):34-9.

41. Weber A, Williams-Warren J, Ramsey B, Smith AL. Tobramycin serum concentrations after aerosol and oral administration in cystic fibrosis. Am J Ther 1995;2(2):81-7.

42. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA, Williams-Warren J, Wadsworth SC, Smith AE, Welsh MJ. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97(6):1504-11.

43. Ramsey BW. What is the role of upper airway bacterial cultures in patients with cystic fibrosis? Pediatr Pulmonol 1996;21(5):265-6.

44. Ramsey BW. Management of pulmonary disease in cystic fibrosis. N Engl J Med 1996;335(3):179-88.

45. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery B, Smith AL, Ramsey BW, Aerosolized Tobramycin Study Group. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997;111(4):955-62.

46. Smith A, Weber A, Pandher R, Williams-Warren J, Cohen ML, Ramsey B. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 1997;25(2):106-8.

47. Rosenfeld M, Cohen M, Ramsey BW. Aerosolized antibiotics for bacterial lower airway infections:

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 7 -

Principles, efficacy and pitfalls. Clin Pulmonary Med 1997;4:101-12.

48. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145(9):794-803.

49. Weber A, Morlin G, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997;23(4):249-60.

50. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, Smith AL. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997;131(1 Pt 1):118-24.

51. Rosenfeld M, Emerson J, Astely S, Joy P, Williams-Warren J, Standaert TA, Yim DL, Crist D, Thykkuttathil J, Torrence M, FitzSimmons S, Ramsey B. Home nebulizer usage among patient with cystic fibrosis. J Pediatr 1998;132(1):125-31.

52. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998;101(6):1013-9.

53. Welsh MJ, Ramsey BW. Research on cystic fibrosis: a journey from the Heart House. Am J Respir Crit Care Med 1998;157(4 Pt 2):S148-54.

54. Standaert TA, Morlin GL, Williams-Warren J, Joy P, Pepe MS, Weber A, Ramsey BW. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998;114(2):577-86.

55. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27(1):158-63.

56. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K N, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL, Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30.

57. Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. J Am Diet Assoc 1999;99(2):191-4.

58. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28(5):321-8.

59. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179(5):1190-6.

60. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 8 -

T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134(4):413-21.

61. Standaert TA, Vandevanter D, Ramsey BW, Vasiljev M, Nardella P, Gmur D, Bredl C, Murphy A, Montgomery AB. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000;13(2):147-53.

62. Standaert TA, Bohn SE, Aitken ML, Ramsey B. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001;14(1):31-42.

63. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey B. Longitudinal assessment of Pseudomonas aeruginosa in young children. J Infect Dis 2001;183(3):444-52.

64. Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogart G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B, Cystic Fibrosis Therapeutics Development Research Group. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study. Pediatr Pulmonol 2001;32(2):122-8.

65. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-65.

66. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, Burns JL, Vincini P, Montgomery AB, Ramsey B. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139(4):572-7.

67. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A Phase 1 study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001;12(15):1907-16.

68. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, Ramsey BW. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32(5):356-66.

69. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91-100.

70. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226. Review.

71. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):841-9.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 9 -

72. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123(5):1495-502.

73. Gibson RL, Burns JL, Ramsey BW. State of the Art: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8)918-51.

74. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis and management. Curr Opin Pulm Med 2003;9(6):492-7.

75. Ernst RK, D’Argenio DA, Ichikawa JK, Bangera MG, Selgrade S, Burns JL, Hiatt P, McCoy, K, Brittnacher M, Kas A, Spencer DH, Olson MV, Ramsey BW, Lory S, Miller SI. Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol 2003;5(12):1341-9.

76. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL,Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-21.

77. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004;59(11):955-59.

78. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005;39(3):209-18.

79. Deterding R, Retstch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, LaVange L, Engels J, Mathews D, Gordon J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor antagonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39(4):339-48.

80. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172(7):885-91.

81. Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML. Clinical trial participants compared to non-participants in cystic fibrosis. Am J Respir Crit Care Med 2006;173:98-104.

82. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5 and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17(4):440-7.

83. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW,

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 10 -

Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. From the cover: Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103(22):8487-92.

84. Ramsey BW. Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report. J Pediatr 2006;149(1 Suppl):S15-9.

85. Sucharew H, Goss CH, Millard SP, Ramsey BW; Cystic Fibrosis Therapeutics Development Network. Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials. Contemp Clin Trials 2006;27(6):561-70.

86. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, William J, Ramsey BW, Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42(7):610-23.

87. Hoffman LR, Deziel E, D'Argenio DA, Lepine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2006;103(52):19890-5.

88. Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. J Cyst Fibros 2007;6(2):117-23.

89. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175(8):822-8.

90. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Respir Cell Mol Biol 2007;published ahead of print on March 8, 2007.

91. D’Argenio DA, Wu M, Hoffman LR, Kulasekara, Deziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 2007;63(2):512-33.

92. Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW. Phase 2 randomized safety and efficacy trial of nebulized Denufosol Tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;176(4):362-9.

93. Ramsey BW. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc 2007;4(4):359-63.

94. Ramsey BW. Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps? Proc Am Thorac Soc 2007;4(4):367-9.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 11 -

95. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4(4):370-7.

96. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007;42(9):751-6.

97. Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI. Unique Lipid A Modifications in Pseudomonas aeruginosa Isolated from the Airways of Patients with Cystic Fibrosis. J Infect Dis. 2007;196:1088-92.

98. Goss CH, Mayer-Hamblett N, Williams J, Ramsey BW. The Cystic Fibrosis Foundation Therapeutics Development Network:  A national effort by the Cystic Fibrosis Foundation to build a clinical trials network. Children’s Health Care 2008;37(1):5-20.

99. Sagel SD , Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis. J Pediatr 2009;154(2):183-8.

100. Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 2009;8(1):66-70.

Manuscripts in Press:

1. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials (2009).

Reviews, Invited Papers, and Book Chapters:

1. Burns JL, Ramsey BW, Smith AL. "Clinical manifestations and treatment of pulmonary infections in cystic fibrosis," In: Advances in Pediatric Infectious Diseases, Vol. 8, Mosby-Year Book, Inc., St. Louis, 1993, pp. 53-63.

2. Rosenfeld M, Ramsey BW. Evolution of airway microbiology in the infant with cystic fibrosis: Role of non-pseudomonal and pseudomonal pathogens. In: Seminars in Respiratory Infections, G.A. Sarosi (Ed.), W.B. Saunders, Philadelphia. 1992, pp. 158-67.

3. Smith AL, Ramsey BW. New trends in aerosol therapy, In: Clinical Ecology of Cystic Fibrosis, H. Escobar, C.F. Baquero, L. Suarez (Eds.) Elsevier Science Publishers, Madrid. 1993, pp. 109-13.

4. Ramsey BW, Smith AL. Letter to the Editor. N Engl J Med 1993;329:1658.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 12 -

5. Marshall S, Ramsey BW. Respiratory system: Pediatrics, In: Cystic Fibrosis, M. Hodson, D. Geddes (eds.), Chapman & Hall, London, 1995, pp. 215-36.

6. Marshall S, Ramsey BW. Respiratory system: Pediatrics, In: Cystic Fibrosis, 2 nd Ed. , M. Hodson, D. Geddes (eds.), Chapman & Hall, London, 1995, pp. 215-36.

7. Welsh MJ, Ramsey BW, Accurso F, Cutting GR: Cystic Fibrosis, In: The Metabolic and Molecular Bases of Inherited Disease, 8 th Ed . Vol. 1, Scriver, Beaudet, Valle, Sly, Childs, Kinzler, Vogelstein (eds.), McGraw Hill, New York, 2001, pp. 5121-88.

8. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226.

9. Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW. The Cystic Fibrosis Therapeutics Development Network (CF TDN): A paradigm of a clinical trials network for genetic and orphan diseases. Adv Drug Deliv Rev 2002;54(11):1505-28.

10. Ramsey BW. To cohort of not to cohort: How transmissible is Pseudomonas aeruginosa? Am J Respir Crit Care Med 2002;166(7):906-7.

11. IOM (Institute of Medicine), Committee on Assessing the System for Protecting Human Research Participants. Responsible research: a systems approach to protecting research participants. Federman DD, Hanna KE, Rodriguez LL, editors. Washington, D.C.: The National Academies Press; 2002.

12. IOM, Board of Health Sciences Policy, Committee on Clinical Research Involving Children. Ethical conduct of clinical research involving children. Field MJ, Behrman RD, editors. Washington, D.C.: The National Academies Press; 2004.

Published Abstracts:

1. Ramsey BW, Cooney MK, Smith AL. Viral and mycoplasma infections in cystic fibrosis. CF Club Abstract 1983;24:43.

2. Ramsey BW, Cooney MK, Smith AL. Viral and mycoplasma infections in cystic fibrosis: do they play a significant role in pulmonary exacerbations? CF Club Abstracts 1984;25:161.

3. Cystic Fibrosis Horizons - Proceedings of the 9th International CF Congress, Brighton, England, June 9, 1984. David Lawson (editor) A Wiley Medical Publications, page 381.

4. Ramsey BW, Smith AL. Quantitative sputum analysis in cystic fibrosis; significance of Pseudomonas aeruginosa colony density. CF Club Abstracts 1984;25:127.

5. Lipnick RN, Fink RJ, Murphy RJ, Hicks TM, Magilavy DB, Schaller JG, Blumhagen JD, Ramsey BW. Hypertrophic osteoarthropathy in cystic fibrosis. CF Club Abstracts 1984;25:99.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 13 -

6. Izutsu K, Ramsey BW, Schuber M, Johnson D, Tamarin A, Morton T, Young M, Mersai T, Truelove E. Intracellular elemental concentrations in labial minor salivary glands of patients with cystic fibrosis. CF Club Abstracts 1984;25:181.

7. Ramsey BW, Marcuse EK. Are the clinical presentation of viral, bacterial and mycoplasma pneumonias different? Ambulatory Pediatrics Association 1984, San Francisco, California.

8. Ramsey BW. Bacterial oropharyngeal cultures to diagnose lower respiratory tract infections in cystic fibrosis. North American CF Conference 1987, Toronto, Canada.

9. Smith AL, Ramsey BW, Hack B, Weber A, Jenny P, Williams-Warren J, Redding G. Safety and efficacy of high-dose aerosol tobramycin in CF patients. The American Pediatric Society 1988.

10. Rucker R, Tremper L, Harwood I, Hernried L, Lewis N, Wang C, Delano M, Dunn K, Davis B, Kurland G, Murphy S, Lemen R, Ramsey BW, Lewiston N. Western CF Data Bank, San Diego, CA. Oral antimicrobial therapy for cystic fibrosis. American College of Chest Physicians; 54th Annual Scientific Assembly 1988.

11. Wang C, Tremper L, Harwood I, Lewis N, Hernried L, Rucker R, Delando M, Dunn K, Davis B, Kurland G, Murphy S, Ramsey BW, Lewiston N. Western CF Data Bank, San Diego, CA. Sputum bacteria in cystic fibrosis patients in the western United States. American College of Chest Physicians; 54th Annual Scientific Assembly 1988.

12. Weber A, deGroot R, Smith A, Hack B, Ramsey BW. Probencid pharmacokinetics in CF subjects and controls. Pediatr Pulmonol 1988;S122.

13. Weber A, Smith A, Hack B, Williams-Warren J, Ramsey BW, Unadkat J. Tobramycin serum pharmacokinetics after aerosol administration. Pediatr Pulmonol 1989;S94.

14. Allen B, Izutsu K, Ramsey BW, Schubert M, Ensign W, Truelove E. Cyclic AMP responses of labial glands from controls and cystic fibrosis patients. IADR 1989.

15. Wentz K, Ramsey BW. Relationship of pharyngeal culture isolates to lower respiratory infection in cystic fibrosis patients. Society for Pediatric Epidemiologic Research 1989.

16. Ramsey BW, Schubert C, Lory S. Use of Exotoxin A gene probe as an epidemiologic marker in cystic fibrosis. North American Cystic Fibrosis Conference. Pediatr Pulmonol 1990.

17. Western Consortium of CF Center Directors. Use of Home Oxygen and Intravenous Antibiotics in the Western United States. North American Cystic Fibrosis Conference 1990.

18. Western Consortium of CF Center Directors. Respiratory Cultures of Cystic Fibrosis Patients in the Western United States. North American Cystic Fibrosis Conference 1990.

19. Unadkat J, Sahajwalla C, McNamara S, Ramsey BW, Smith AL. Metabolic Clearance of Sulfamethoxazole in Cystic Fibrosis. Pediatr Pulmonol 1990.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 14 -

20. Ramsey BW. Limitations and Potential Problems Associated with the Use of Aerosolized Medications in Cystic Fibrosis Patients. Pediatr Pulmonol 1990.

21. Ramsey BW, Smith AL, Williams-Warren J, Astley S, McBurnie M, Hedges D. The Efficacy of Aerosolized Tobramycin Administration in Cystic Fibrosis Patients: Results of a Multi-center, Placebo-controlled, Cross-over Trial. Pediatr Pulmonol 1991.

22. McNamara S, Ramsey BW, Morlin G, Astley S, Dossey R, Hiatt P, Lawrence C, McCoy K. P. aeruginosa Colonization and Serologic Response in Young Children with Cystic Fibrosis. Pediatr Pulmonol 1994;S11.

23. Eisenberg J, Eagen T, Ramsey B (for the CF Research Consortium). Safety, efficacy and pharmacokinetics of tobramycin (Tobra) administered by three different nebulizer delivery systems. Pediatr Pulmonol 1994;S11.

24. Rosenfeld MR, Davis R, Pepe M, Ramsey BW. Differences in survival by gender among US cystic fibrosis patients. Pediatr Pulmonol 1995;S12.

25. Standaert T.A, Morlin G, Weber A, Pepe M, Ramsey BW. The performance of disposable jet nebulizers after repeated use. North American Cystic Fibrosis Conference. Pediatr Pulmonol 1995;S12.

26. Burns JL, Yim DL, Stapp JR, Ramsey BW, Clausen CR. Microbiology of CF sputum samples from 69 U.S. centers. Pediatr Pulmonol 1996;S13:295.

27. Joy P, Rosenfeld M, Emerson J, Williams-Warren J, Yim D, Standaert T, Astley S, Torrence M, FitzSimmons S, Ramsey BW. Home nebulizer usage among CF patients. Pediatr Pulmonol 1996;S13:309.

28. Ramsey BW. New clinical developments: From the test tube to the bedside. Pediatr Pulmonol 1997;S14:72.

29. Ramsey BW, Burns J, Smith A. Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials. Pediatr Pulmonol 1997;S14:137-8.

30. MacLeod DL, Shawar RM, Nelson LE, Lockwood LG, Lin BE, Dirks JE, Burns JL, Ramsey BW, Garber RL. Molecular investigation of high-level tobramycin resistance. Pediatr Pumonol 1997;S14:289.

31. Lin BB, Dirks JE, MacLeod DL, Lockwood LG, Burns JL, Ramsey BW, Garber RL. Molecular epidemiology of Pseudomonas aeruginosa strains from cystic fibrosis patients receiving aerosolized tobramycin. Pediatr Pulmonol 1997;S14:289.

32. Burns JL, Yim D, McNamara S, Emerson J, McCoy K, Hiatt P, Ramsey BW. CF microbiology in young children. Pediatr Pulmonol 1997;S14:293.

33. McNamara S, Ramsey BW, Emerson J, Ingham L, Crist D. P. aeruginosa colonization in young children with cystic fibrosis. Pediatr Pulmonol 1997;S14:293.

34. Standaert TA, Ramsey BW, Vasiljev-K. M, Montgomery B. Evaluation of aerosolized tobramycin delivery

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 15 -

by 4 major European nebulizers. Pediatr Pulmonol 1997;S14:295.

35. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Ramsey BW. Defining a pulmonary exacerbation in cystic fibrosis. Pediatr Pulmonol 1997;S14:295.

36. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey BW, Wagener J. Diagnostic accuracy of oropharyngeal cultures relative to lower airway cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1997;S14:295.

37. Ramsey BW, McNamara S, Gibson R, Emerson J, Rosenfeld M, Hiatt P, McConnell R, McCoy K, Lawrence C, Olson P. P. Aeruginosa (Pa) colonization in young children with cystic fibrosis. North American Cystic Fibrosis Conference. Pediatr Pulmonol 1998;S14.

38. Standaert TA, Ramsey BW. Compressor performance alters aerosolization characteristics of jet nebulizers. Pediatr Pulmonol 1998;S15.

39. Burns J, McNamara S, Yim D, Krzewinski J, Emerson JC, Wilson CB, Ramsey BW. Immune response to lower airway infection in young children with CF. North American Cystic Fibrosis Conference. Pediatr Pulmonol 1998;S15.

40. Vicini P, Rosenfeld M, Borowitz D, McCoy K, McNamara S, Montgomery B, Ramsey BW, Wilmott B. Population pharmacokinetics of inhaled tobramycin in cystic fibrosis patients less than 6 years of age. Pharm Sci 1999;S1(4):1602-3.

41. Rosenfeld M, Borowitz D, Emerson J, Gibson R, McCoy K, McNamara S, Montgomery B, Ramsey B, Vicini P, Wilmott B. Serum pharmacokinetics and safety of inhaled tobramycin in very young patients. Pediatr Pulmonol 1999;S19:262.

42. Ramsey B, Waltz D, Rodman D, Redman R, Michaels J, Haelsen M, Johnson C, Hamblett N, Fujii C, Lowry D for The Iseganan CF Investigators: CF Therapeutics Development Network. Pediatr Pulmonol 2000.

43. Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML. Clinical trial participants compared to non-participants in cystic fibrosis. Pediatr Pulmonol 2000;S20:315.

44. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A phase I study of aerosolized administration of tgAAVCF to CF patients with mild lung disease. Pediatr Pulmonol 2000;S20:236.

45. Ramsey B, Rodman D, Redman R, Michaels J, Haelsen M, Johnson C, Hamblett N, Fujii C, Loury D. A phase I safety and tolerability study of ascending multiple doses of aerosolized iseganan HCI solution (IB-367) in adults with cystic fibrosis. Pediatr Pulmonol 2001;S22:263.

46. Goss CH, Mayer-Hamblett N, Yunker A, Waltz DA, Kronmal RA, Ramsey BW. Laboratory parameter profiles among patients with cystic fibrosis. Am J Rep Crit Care Med 2002.

47. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 16 -

M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R, Wagener J, Zeitlin P, Ramsey B. A randomized, controlled trial of inhaled tobramycin in young children with cystic fibrosis: Eradication of Pseudomonas from the lower airway. Pediatr Pulmonol 2002;S24:300.

48. Deterding R, Mundahl J, Shaffer C, Kellerman D, Mathews D, LaVange L, Gorden J, Quittner A, Williams J, Ramsey B. Safety and tolerability of INS37217 inhalation solution, a novel P2Y2 receptor agonist, in patients with mild to moderate cystic fibrosis: Results of a phase 1/2 multicenter study. Pediatr Pulmonol 2002;S24:258.

49. Moss R, Wagener J, Daines C, Hale K, Ahrens D, Gibson R, Anderson, Retsch-Bogart G, Nasr S, Noth I, Waltz D, Zeitlin P, Ramsey B, Hamblett N, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b (IFN-ylb) in patients with mild-moderate cystic fibrosis lung disease. American Thoracic Society 2003.

50. Moss R, Rodman D, Spencer T, Aitken M, Zeitlin P, Waltz D, Milla C, Brody A, Clancy JP, Ramsey B, Mayer-Hamblett N, Johnson C, Pedersen P, Heald A. A multicenter, double-blind, placebo-controlled, phase II study of aerosolized tgAAVCF in cystic fibrosis (CF) patients with mild lung disease. Pediatric Academy Society 2003.

51. Caron H, Millard S, Goss C, Ramsey B. Respiratory adverse event profiles in placebo subjects in short-and long-term inhaled therapies. Pediatr Pulmonol 2003 (Suppl 25): p334, A432.

52. Waltz D, Gibson R, McNamara S, Campbell J, Hamblett N, Ramsey B. Safety and yield of clinical trial bronchoscopy procedures in young cystic fibrosis patients. Pediatr Pulmonol 2003 (Suppl 25): p 320, A393.

53. Gibson R, Emerson J, McNamara S, Burns J, Rosenfeld M, Hamblett N, Borowitz D, Daines C, Hiatt P, Konstan M, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Zeitlin P, Ramsey B. Duration of the anti-pseudomonal treatment effect on inhaled tobramycin in young children with cystic fibrosis. Pediatr Pulmonol 2003 (Suppl 25): p295, A323.

54. Deterding RR, La Vange L, Matthews D, Engels J, Gorden J, Shaffer C, Coquillette S, Ramsey B. Safety and efficacy of INS37217 inhalation solution, a novel P2Y2 receptor agonist, in patients with mild cystic fibrosis: results of a Phase 2 multi-center study. Pediatr Pulmonol 2004 (Suppl 27): p249, A177.

55. Moss RB, Milla C, Colombo J, Clancy JP, Zeitlin P, Spencer T, Accurso F, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P, Heald AE. A multicenter, double-blind, placebo-controlled, Phase 2b study of aerosolized TgAAVCF for the treatment of cystic fibrosis. Pediatr Pulmonol 2004 (Suppl 27): p257-8, A201.

56. Goss CH, Sucharew H, McKone EF, Lechzin N, Dubley C, Aitken ML, Ramsey BW. Nutritional supplementation in the US cystic fibrosis population with severe pulmonary impairment. Pediatr Pulmonol 2004 (Suppl 27): p349, A456.

57. Ramsey BW. TOBI use in infants and children with early Pseudomonas aeruginosa infection - duration of effect and EPIC update. Pediatr Pulmonol 2005 (Suppl 28): p146-7, S12.4.

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 17 -

58. Chmiel JF, Konstan MW, Lymp J, Mayer-Hamblett N, Hilliard KA, Accurso FJ, Ramsey B. Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF. Pediatr Pulmonol 2007 (Suppl 30): p228-9, A81.

59. Rosenfeld M, Gibson R, Emerson J, McNamara S, Escobar DM, Andrina M, Chatfield BA, Orenstein DM, Konstan MW, Rock M, Wall M, Ramsey BW. Large US cohort of young pseudomonas negative CF patients: mild lung disease, heterogeneous management. Pediatr Pulmonol 2007 (Suppl 30): p332, A368.

60. Lymp JF, Khan U, Ramsey BW, Konstan MW. Pulmonary exacerbation outcomes in the cystic fibrosis population: variations in rates and sample size implications. Pediatr Pulmonol 2007 (Suppl 30): p350, A416.

61. Goss CH, Edwards T, Levenson L, Ramsey BW, Aitken ML, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis: development of a novel instrument. Pediatr Pulmonol 2007 (Suppl 30): p408-9, A570.

62. Goss CH, Edwards T, Lymp JF, Cooper P, Ramsey BW, Aitken M, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis: initial validation. Pediatr Pulmonol 2007 (Suppl 30): p409, A571.

63. Moss R, Milla C, Colombo J, Accurso F, Zeitlin P, Clancy J, Spencer L, Pilewski J, Waltz D, Dorkin H, Ferkol T, Pian M, Ramsey B, Carter B, Martin D, Heald A. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled Phase 2B trial. Hum Gene Ther 2007;18(8):726-32.

TEACHING:

Pulmonary fellows:

1992-1995 Margaret Rosenfeld1997-2000 Chris Goss1997-2001 Sam Moskowitz2000-2003 Jason Debley2001-2005 Luke Hoffman2005- Dan HsaiResidents:

2006- Chelsea Bodnar2004- Jessica Pittman

Seminars, presentations and invited lectureships:

1. Advances in CF Care: From the Test Tube to the Bedside, NACFC Plenary Session, Nashville, 1997

2. Science in Medicine Lecture, University of Washington, Seattle, 1997

3. CF Research Update, Annual All Day Parent Symposium, Seattle, 1997

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 18 -

4. Long-Term Safety and Efficacy of Inhaled Tobramycin (TOBI ) in Patients with Cystic Fibrosis, NACFC Plenary Session, Montreal, 1998

5. Death and Dying, Intern Retreat, University of Washington, 1998, 2001

6. Advances in CF Care, Grand Rounds, Arkansas, 1998

7. New Therapies in Cystic Fibrosis: An International Effort, NACFC, Seattle, 1999

8. Pulmonary Management of Cystic Fibrosis for the Primary Care Physician, Houston, 1999

9. The Next Challenge in Cystic Fibrosis: Developing New Therapies, Grand Rounds, Houston, 1999

10. New Therapies in Cystic Fibrosis: An International Effort, NACFC, Seattle, 1999

11. Grand Rounds, Dallas, Forth Worth, Little Rock, 1999

12. Clinical Trials in Cystic Fibrosis, Keystone Symposium, Park City, Utah, 1999

13. Human Bio 512, Medical Student Lecture, University of Washington, Seattle, 2000, 1999, 1998, 1997

14. The Next Challenge in Cystic Fibrosis: Developing New Therapies, New Zealand, 2000

15. Pulmonary Management of Cystic Fibrosis for the Primary Care Physician, New Zealand, 2000

16. Cystic Fibrosis Drug Development Proposal, William Gates Foundation, Seattle, 2001

17. Clinical Research in Cystic Fibrosis: How Do We Develop New Therapies to Improve the Lives of Patients with CF?, Congressional, 2001

18. Conduct of Research Involving Human Participants: A Working Document, Institutes of Medicine, WA DC, 2001

19. Conduct and Regulation of Human Clinical Trials, Law Seminars, Seattle, 200120. The Next Challenge in Cystic Fibrosis: Developing New Therapies, Washington Department of Health

Conference, Kent, 2001

21. Developing Better Therapies for Patients With Cystic Fibrosis: 2002 Progress Report, Plenary Session, NACFC, New Orleans, 2002

22. Developing New Therapeutic Agents in Cystic Fibrosis: Advantages and Challenges, Williamsburg Conference, Virginia, 2002

23. Limitations for Gene Therapy, Grand Rounds, Seattle, 2002

24. Cystic Fibrosis Part 1, Noon Housestaff Lecture, CHRMC, Seattle, 2004, 2002

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 19 -

25. Cystic Fibrosis Part 2, Noon Housestaff Lecture, CHRMC, Seattle, 2005, 2002

26. Can We Have an Earlier Impact on Disease Progression in CF?, Midwest Consortium, St. Louis, 2002

27. Pulmonary Management of Cystic Fibrosis, Bellingham Visiting Professor, 2003

28. Ethical Issues in Performing Clinical Research in Pediatric Patients, Clinical Research Workshop Series, Seattle, 2003

29. Is There Sufficient Evidence to Advocate Early Intervention for Pseudomonas Acquisition?, Debate, NACFC, 2003

30. Controversies in Pediatric Research, NACFC, 2003

31. Efficacy and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas aeruginosa Airway Infection in Young Patients with Cystic Fibrosis, Center Directors Meeting, NACFC, 2003

32. Update of Anti-Pseudomonal Therapies for New Onset P. aeruginosa Infection, CF Gene Therapy Seminar Series, University of Washington, 2003

33. Developing New Therapies for Patients with Cystic Fibrosis: A Five Year Progress Report From the CF Therapeutics Development Network, European Cystic Fibrosis Conference, Australia, 2003

34. Infection Control Recommendations for Patients With Cystic Fibrosis, European Cystic Fibrosis Conference, Australia, 2003

35. Designing Clinical Trials in Cystic Fibrosis, European Cystic Fibrosis Conference, Australia, 2003

36. Cystic Fibrosis (CF) in Adults: A Primer for the Practicing Pulmonologist, American Thoracic Society Annual Conference, 2003

37. Institute of Medicine (IOM) Committee on Assessing the National System for Protecting Human Research Participants 2000-2002, UW Clinical Investigators Conference, Seattle, 2003 and IRB Annual Luncheon, CHRMC, Seattle, 2003

38. Investigations in CF: How Basic Science and Clinical Research Are Interacting Synergistically to Defeat This Dread Disease, Chest Conference Plenary Session, Seattle, 2004

39. Developing New Therapies for Patients with Cystic Fibrosis, GI Grand Rounds, University of Washington, 2004

40. Ethical Conduct of Clinical Research Involving Children: The Institute of Medicine Report, Annual Pediatric Bioethics Conference, Seattle, 2005

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 20 -

41. CF Care Centers and Quality Improvement, CF Parent Day, CHRMC, 2005

42. Development of New Antimicrobial Therapies: How Can the CF Community Successfully Partner with Industry and FDA?, CFF Antimicrobial Taskforce, Bethesda, 2005

43. Use of Lung Imaging Studies in Phase 1, 2 and 3 Clinical Trials in CF, HRCT Consensus Conference, 2005

44. TOBI Use in Infants and Children with Early Pseudomonas aeruginosa Infection: Duration of Effect and EPIC Update, NACFC, 2005

45. Strategies for the Clinical Development Plan for Inhaled Ciprofloxacin (IC), Bayer Corporation, 2005

46. Management of Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: A Twenty Year Odyssey, CHRMC Residents, 2006

47. New Therapies and Clinical Trials, CF Parent Day, CHRMC, 2006

48. The Cystic Fibrosis Therapeutics Development Network (CF-TDN): Bridging the Gap Between Promising Laboratory Findings and Potential New Therapeutic Approaches in CF, European Society Cystic Fibrosis Conference, 2006

49. Cystic Fibrosis (CF): A Paradigm for Translational Medicine, WWAMI Retreat, University of Washington, 2006

50. Cystic Fibrosis (CF): A Paradigm for Translational Medicine, MedEx Grand Rounds, University of Washington, 2007

51. Cystic Fibrosis: Current Understanding of the Disease and Novel Therapeutic Approaches, Medical Genetics Molecular Seminar, University of Washington, 2007

52. Clinical Trial Design Considerations for Developing a Phase 3 Pivotal Trial for PTC-124, PTC Advisory Meeting, 2007

53. What is New in Pulmonary Management of Cystic Fibrosis, WWAMI Visiting Professor, Port Angeles, 2007

54. Novel Therapeutic Approaches to Treatment of Cystic Fibrosis Lung Disease: the Road to a Cure, Kossoff Lecture and Visiting Professor, Columbia University, 2007

55. Cystic Fibrosis (CF): A Paradigm for Translational Medicine, Pediatric Grand Rounds, Rochester, NY, 2007

56. Drug Development in Orphan Diseases: the Power of a Clinical Trials Network in Cystic Fibrosis, Grand Rounds and Visiting Professor, Rotterdam, Netherlands, 2007

57. Developing a Clinical Trials Network, European Society for Cystic Fibrosis (ESCF) Meeting, Leuven, Belgium, 2007

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 21 -

58. How Do We Develop New Therapies to Improve the Lives of Patients with CF? CF Parent Day 2008

59. Understanding Cystic Fibrosis, CF Parent Day 2008

60. What Should CF Care Be Like in 2020, Postgraduate Course, American Thoracic Society International Conference, Toronto 2008

61. Enhancing Clinical Investigation by Improved Management Workshop, Roundtable Discussion Facilitator, Bethesda, MD, 2008

62. Sources of Clinical Research Questions; Interplay between Clinical Research and Clinical Practice, Interdisciplinary Clinical Research Course, University of Washington, 2008

63. Translational Science is Best Achieved through Team Research – Cystic Fibrosis as a Model, Seattle Children’s Research Institute Symposium, 2008

64. Anatomy of a Clinical Trial in CF; how the Therapeutics Development Network has Impacted on this Process, Cystic Fibrosis Research Retreat, University of Pennsylvania, 2008

65. Competing Priorities in Clinical Research: Balancing Needs of Patients, Investigators and Sponsors, Emerging Bioethical Topics in Cystic Fibrosis Research and Clinical Care Workshop, North American Cystic Fibrosis Conference, Orlando 2008

Curriculum Vitae Bonnie W. Ramsey, MD Revision Date: 05/21/23 - 22 -